About Jimena Vicencio

Articles by Jimena Vicencio, MD

Building Community and Support for Caregivers with Social Media
Nov 10, 2025
Curcumin for MPN: Exploring a Natural Compound’s Potential
Nov 04, 2025
Supporting Caregivers: When They Thrive, Patients Do Too
Nov 04, 2025
$FDA Approves Revumenib for Relapsed or Refractory AML with NPM1 Mutation image$

FDA Approves Revumenib for Relapsed or Refractory AML with NPM1 Mutation
Oct 27, 2025
Treatment Advances Updates for Monoclonal Gammopathy of Renal Significance (MGRS)
Oct 24, 2025
A Landmark Transplant: First Stem Cell Transplant from Deceased Donor
Oct 24, 2025
What Are The Differences Between Cytopenic And Proliferative Myelofibrosis?
Oct 16, 2025
Want a Better Understanding of CAR T-cell Therapy for Multiple Myeloma? Start Here
Oct 13, 2025
Understanding Splenomegaly and Splenectomy in Myelofibrosis
Oct 07, 2025
$Sonrotoclax Combination for Relapsed/Refractory AML image$

Sonrotoclax Combination for Relapsed/Refractory AML
Sep 30, 2025
Busulfan-Fludarabine vs. Busulfan-Cyclophosphamide in Stem Cell Transplant Conditioning
Sep 29, 2025
What is the Bence Jones Protein?
Sep 26, 2025
The Future of Risk Prediction and Monitoring in Multiple Myeloma
Sep 22, 2025
In Case You Missed it: Myelofibrosis Updates
Sep 20, 2025
Evaluating Venetoclax as a Maintenance Therapy After Transplant for AML Patients
Sep 19, 2025
In Case You Missed It: What’s New in Smoldering Myeloma?
Sep 18, 2025
How To Safely Incorporate Complementary Medicine in Cancer Care
Sep 12, 2025
Trial Results of FLAG-IDA and Venetoclax for AML
Sep 08, 2025
In Case You Missed it: What’s New in MPN Research
Sep 08, 2025
Identifying Patients with Systemic AL Amyloidosis at the Highest Risk
Sep 08, 2025
Olutasidenib and Azacitidine for Myelodysplastic Syndromes with IDH1 Mutations
Sep 08, 2025
What is Light-Chain Deposition Disease?
Sep 04, 2025
September is Blood Cancer Awareness Month: Special Events & Resources
Sep 01, 2025
What You Need to Know About Respiratory Viruses in 2025
Sep 01, 2025